Measuring response with FDG-PET: methodological aspects.
The use of fluorodeoxyglucose positron emission tomography (FDG-PET) for the evaluation of tumor response to chemotherapy and radiation therapy has been studied in a number of malignancies. By imaging tumor metabolism and therapy-related changes, FDG-PET has demonstrated advantages over anatomical imaging in the assessment of treatment response. More recent investigations have indicated that FDG-PET can predict tumor response early during the course of therapy, potentially allowing for early treatment adjustments. The aim of this review is to provide oncologists with a basic knowledge of the practical aspects of PET quantification for treatment.
Allen-Auerbach
Martin
M
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, CA 90095-6942, USA. mauerbach@mednet.ucla.edu
Weber
Wolfgang A
WA
D000465:Algorithms; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging / Q000378:metabolism; D017024:Chemotherapy, Adjuvant; D004938:Esophageal Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism*; D006689:Hodgkin Disease / Q000000981:diagnostic imaging / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging / Q000378:metabolism; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D049268:Positron-Emission Tomography / Q000379:methods; D011379:Prognosis; D019275:Radiopharmaceuticals / Q000378:metabolism*; D018714:Radiotherapy, Adjuvant; D002583:Uterine Cervical Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18